This is a working overview of Investigational drug, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-08. Anything still debated is marked as such rather than presented as settled.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a metabolic modulator. |
| Approved medical use | None in major jurisdictions | Not a registered drug. |
| Common test matrix | Urine | Most anti-doping samples use urine. |
| Typical detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Reference standard storage | -20 °C, desiccated | Typical for analytical standards. |
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Somalia is a semi-arid country with about 1.6% arable land. The first local environmental organisations were Ecoterra Somalia and the Somali Ecological Society, which promoted ecological awareness and mobilised environmental programs governmentally and through grassroots efforts. From 1971 onward, a massive tree-planting campaign on a nationwide scale was introduced by the communist government to halt the advance of wind-driven sand dunes, which threatened to engulf towns, roads and farm land. By 1988, 265 hectares of a projected 336 hectares had been treated, with 39 range reserve sites and 36 forestry plantation sites established. In 1986, the Wildlife Rescue, Research and Monitoring Centre was established by Ecoterra International, with the goal of raising ecological awareness. This effort led in 1989 to a decision by the Somali government to adhere to the Convention on International Trade in Endangered Species of Wild Fauna and Flora, which banned the trade of elephant ivory. Following the tsunami of December 2004, it was alleged that Somalia's shoreline was used to dump toxic waste. The waves after the tsunami stirred up nuclear and toxic waste that was possibly dumped illegally by foreign firms.
NAD bound to proteins in the Protein Data Bank NAD Animation (Flash Required) β-Nicotinamide adenine dinucleotide (NAD+, oxidized) and NADH (reduced) Chemical data sheet from Sigma-Aldrich NAD+, NADH and NAD synthesis pathway at the MetaCyc database List of oxidoreductases Archived 30 November 2010 at the Wayback Machine at the SWISS-PROT database NAD+
=== Tolerance === Clinical research has not demonstrated drug tolerance, a reduction in wakefulness-promoting and anti-fatigue effects, as a common outcome, even with therapeutic use extending up to 40 weeks. However, long-term use can lead to tolerance in some individuals, necessitating higher doses to maintain efficacy. People with current or past substance addictions and those with a family history of addiction are at higher risk. The underlying mechanisms, which may involve dopamine and norepinephrine pathways, are not fully understood. Tolerance appears more likely with off-label use for cognitive enhancement than with therapeutic use for narcolepsy, where effectiveness does not usually diminish with prolonged treatment.
=== Legal status === The US Food and Drug Administration (FDA) approved tranexamic acid oral tablets (brand name Lysteda) for the treatment of heavy menstrual bleeding in November 2009. In March 2011, the status of tranexamic acid for the treatment of heavy menstrual bleeding was changed in the UK, from POM (Prescription only Medicines) to P (Pharmacy Medicines) and became available over the counter in UK pharmacies under the brand names of Cyklo-F and Femstrual.
Sources: en.wikipedia.org
The Essendon Football Club supplements saga was a sports drug doping controversy that occurred during the early- and mid-2010s. It centred around the Essendon Football Club, nicknamed the Bombers, a professional Australian rules football club based in Melbourne and playing in the Australian Football League (AFL). The club was investigated starting in February 2013 by the Australian Sports Anti-Doping Authority (ASADA) and the World Anti-Doping Agency (WADA) over the legality of its supplements program during the 2012 AFL season and the preceding preseason. After four years of investigations and legal proceedings, thirty-four players at the club were found guilty of having used the banned peptide Thymosin beta-4 and incurred suspensions. The initial stages of the investigation in 2013 made no findings regarding the legality of the supplements program. Still, they highlighted a wide range of governance and duty-of-care failures relating to the program. In August 2013, the AFL fined Essendon $2 million, barred the club from the 2013 finals series, and suspended senior coach James Hird and general manager Danny Corcoran as a result of these findings. The second phase of the investigation resulted in thirty-four players being issued show cause notices by ASADA and infraction notices by the AFL in 2014, alleging the use of Thymosin beta-4 during the 2012 season. After facing an AFL Tribunal hearing in the 2014/15 offseason, the players were initially found not guilty.
In commenting on humanity's evolution from an ancient primate ancestor, Jung wrote: "We keep forgetting that we are primates and that we have to make allowances for these primitive layers in our psyche." Jung also developed the notion of different evolutionary layers in the psyche in his discussion of fossil hominins such as Pithecanthropus (Homo erectus). As he writes:
Seaspeed began operating from Dover's Eastern Docks in 1968. British Rail built a new hoverport at the Western Docks, which opened for service in July 1978 (costing some £14 million compared to the original estimate of £8 million). The aim was twofold; one, to cater for the increase in the fleet capacity to four, with the prospect of two new French hovercraft entering the fleet, as well as to handle additional passenger volumes via the extended SR.N4s. Seaspeed would thus be able to compete with Hoverlloyd's operations in Pegwell Bay. two, to provide a direct rail link to London and attract business class professionals, a rail connection was envisaged, similar to that at Boulogne (Le Portel) Hoverport which had been developed in 1968. In the event, only one of the French vessels was deemed fit for purpose and it retired early in 1983, plagued by malfunctions and limitations. Moreover, the direct rail link via Dover Western Docks never materialised and a bus service ran to and from the station instead. The terminal was officially opened by the Duke of Kent in September 1981. After the closure of Hoverspeed in 2005, the Dover Hoverport remained unused. In February 2007, SpeedFerries signed a lease on the former Dover Hoverport, though not the terminal building, moving there from the Eastern Docks. SpeedFerries went into administration in November 2008, which saw the cessation of services to Boulogne. The hoverport site was redeveloped in 2009.
In petrol engines, instead, the vacuum is typically obtained as a side-effect of the operation of the engine and the flow restriction created by the throttle plate but may be also supplemented by an electrically operated vacuum pump to boost braking assistance or improve fuel consumption. This vacuum may then be used to power the following motor vehicle components: vacuum servo booster for the hydraulic brakes, motors that move dampers in the ventilation system, throttle driver in the cruise control servomechanism, door locks or trunk releases. In an aircraft, the vacuum source is often used to power gyroscopes in the various flight instruments. To prevent the complete loss of instrumentation in the event of an electrical failure, the instrument panel is deliberately designed with certain instruments powered by electricity and other instruments powered by the vacuum source. Depending on the application, some vacuum pumps may either be electrically driven (using electric current) or pneumatically driven (using air pressure), or powered and actuated by other means.
The boiling point of a solution of an involatile solute is higher than that of the pure solvent, and the boiling-point elevation (ΔT) is directly proportional to the amount concentration for dilute solutions. When the composition is expressed as a molality, the proportionality constant is known as the ebullioscopic constant (Kb) and is characteristic for each solvent. If w represents the mass fraction of the solute in solution, and assuming no dissociation of the solute, the molar mass is given by
Sources: en.wikipedia.org
Legal status varies by country, but cardarine is not approved as a medicine in major jurisdictions. It is often sold as a research chemical, a category that may not be lawful for human use. Buyers should check local laws and product labels carefully.
Anti-doping laboratories use LC-MS/MS to detect GW501516 and its metabolites, usually in urine. The method can identify the parent compound at low concentrations. Detection windows vary with dose and individual factors.
No, cardarine has no approved medical uses in major jurisdictions. Early research explored metabolic conditions, but those programs were discontinued. It is not a registered treatment for any disease.
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.